Abstract: Embodiments of the invention relate to generating backups of applications. The user or administrator that monitors the backup is notified of those files and/or folders that have not been backed up in the most recent backup. Further, embodiments of the invention enable alerts to be initiated when a particular file or folder has not been backed up over multiple backups or over a predetermined period. As a result, the user or administrator can have a better understanding of the protection and lack of protection that the present backups are providing.

Abstract: A method for performing a data backup process on a cluster includes: obtaining a backup generation request for virtual machines; in response to obtaining the backup generation request: generating a first set of backup groupings based on the backup generation request where each of the first set of backup groupings includes at least one of the virtual machines; issuing a disable migration command to a plurality of production hosts where each of the plurality of production hosts is associated with at least one of the virtual machines; identifying, after the issuing, a virtual machine of the virtual machines that is migrating; removing, based on the identifying, the virtual machine from the first set of backup groupings to obtain a second set of backup groupings where the virtual machine is placed in an excluded group after the removing; and backing up the second set of backup groupings.

Abstract: Compounds having activity as inhibitors of ENPP1 are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof, wherein L, R1, R2a, R2b, R2c, R2d, R2e and n are as defined herein. This disclosure provides methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds, and methods for treating disorders associated with ENPP1, including uncontrolled cellular proliferation, cancer and virial or bacterial infections in a mammal.

Abstract: The present invention provides processes for preparation of substituted pyrazole compounds of formula II, that can be used as intermediates for preparation of substituted piperidine urea compounds useful for the treatment of dilated cardiomyopathy (DCM). R2 is independently selected from F, C1-C4 alkyl, C1-C4 haloalkyl, R3 is independently selected from H, F, C1-C4 alkyl, C1-C4 haloalkyl, R4 is C1-C4 alkyl, R6 is H or a protecting group and R7 is selected from H, CI or trialkylsilyl.

Abstract: Compounds having activity as anti-cancer agents are provided. The compounds have the following structure (I) or a pharmaceutically acceptable salt, stereoisomer or tautomer, thereof, wherein X, Y, R1, R2, R3R4, R5 and L are as defined herein. This disclosure provides methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds, and methods for treating a CDK7-dependent disease (e.g., cancer).

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for receiving training data for multiple datasets that include information about a computing process. The training data is received at a computing system that includes a data manager, a data classifier, and a machine learning (ML) system. The data classifier annotates the training data as being associated with a particular dataset and as being descriptive of computing processes executed to perform transactions. The ML system receives the annotated training data and data about a transaction operation of the system, trains a predictive model to generate prediction data that indicates a runtime condition of the system, and provides the prediction data to a process automation module of the system. The module executes process automation scripts to remediate the computing process, where the computing process is executed by the system to perform the real-time transaction operation.

Abstract: The present invention provides a method for educating and expanding tumor infiltrating lymphocytes (TILs) into a therapeutic population of TILs for adoptive cell immunotherapy. Also provided are methods of treating cancer patients with the therapeutic population of TILs.

Abstract: Compounds and methods for their preparation and use as therapeutic or prophylactic agents, for example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1).

Abstract: A system for monitoring rotating equipment. The system includes a sensor device that acquires vibration data, acoustic emission data, temperature data, and magnetic flux data of the rotating equipment. The sensor device includes base, holding frame, first integrated circuit, housing, and power source. The first integrated circuit includes a plurality of sensors and a microcontroller configured to receive vibration data, acoustic emission data, temperature data, magnetic flux data from plurality of sensors and determine anomalies of the rotating equipment. The system further comprises an application server that receives vibration data and magnetic flux data, determines revolutions per minute (RPM) data for rotating equipment, and diagnose faults based on processed vibration data and RPM data. The application server further generates a set of features and corresponding feature values and analyzes them to diagnose faults, and predict remaining useful life of the rotating equipment.

Abstract: Systems and methods for sleep apnea and nocturnal hypoxia detection are described. In one non-limiting example, a pulse oximetry device can include a sensor and a computing device. The computing device can be attached to a patient for a sleep apnea diagnosis. The computing device can be configured to generate pulse oximetry data by measuring pulse oximetry of a patient with the sensor. Multiple apnea indicators can be identified from the pulse oximetry data and from information associated with the patient. The multiple sleep apnea indicators can be provided to a machine learning model trained for sleep apnea prediction. A sleep apnea classification can be determined from the machine learning model.

Abstract: Compounds and methods for their preparation and use as therapeutic or prophylactic agents, for example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1).

Abstract: The present invention provides methods of maturing a peptide library and of identifying peptides having increased specific binding to a target molecule and/or differential specific binding to target molecules. The present invention also provide methods of developing diagnostic assays, detection kits and therapeutic agents with the peptides.

Abstract: A segmentation platform enables a system that comprises a behavior service and a predictive service for determining a segment from a dataset. The behavior service can analyze data to determine information about behavior that has already occurred. The predictive service can analyze data to determine information about the predicted propensity for certain behavior to occur in the future. In some cases, the predictive service can determine the information by utilizing a training model that indicates predictions related to potential relationships among properties of a dataset. The segmentation platform also enables an interactive user interface that can be utilized to configure attributes of the segment, analyze information associated with the segment, and deliver the information to another device.

Abstract: An SRAM array circuit in which a horizontal N-well of a well tap cell in a first row separated from a horizontal N-well of a well tap cell in a second row by a P-type substrate region is disclosed. The well tap cells include a bilateral P-type well tap disposed in the P-type substrate region between the horizontal N-wells in the first and second rows providing ground voltage to the P-type substrate on both sides of a column of well tap cells in the SRAM array circuit, rather than one P-type well tap for each side. Well tap cells without a vertical N-well reduces width, which corresponds to a reduction in width of the SRAM array circuit. The bilateral P-type well tap in a P-type implant region may include a plurality of folded fingers providing the ground voltage to the P-type substrate.

Abstract: An SRAM array circuit in which a horizontal N-well of a well tap cell in a first row separated from a horizontal N-well of a well tap cell in a second row by a P-type substrate region is disclosed. The well tap cells include a bilateral P-type well tap disposed in the P-type substrate region between the horizontal N-wells in the first and second rows providing ground voltage to the P-type substrate on both sides of a column of well tap cells in the SRAM array circuit, rather than one P-type well tap for each side. Well tap cells without a vertical N-well reduces width, which corresponds to a reduction in width of the SRAM array circuit. The bilateral P-type well tap in a P-type implant region may include a plurality of folded fingers providing the ground voltage to the P-type substrate.

Abstract: An IC includes a first memory block, a second memory block, and a first memory border cell between the first memory block and the second memory block. The first memory border cell includes a first memory core endcap to the first memory block on a first side of the cell. The first memory border cell further includes a second memory core endcap to the second memory block on a second side of the cell. The second side is opposite the first side. The first memory border cell further includes a memory gap portion between the first memory core endcap and the second memory core endcap. The memory gap portion provides a gap between the first memory core endcap and the second memory core endcap.

Abstract: Compounds and methods for their preparation and use as therapeutic or prophylactic agents, for example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1).

Abstract: Compounds having activity as cancer agents are provided. The compounds have the following structure (I) or a pharmaceutically acceptable salts, stereoisomers, tautomers, thereof, wherein R1, R2, R3 and L are as defined herein. This disclosure provides methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds, and methods for treating a CDK7-dependent disease (e.g., cancer).

Abstract: Phosphonate conjugates, preferably, bisphosphonate conjugates; methods of inhibiting Ron receptor tyrosine kinase and methods of treatment of bone destruction due to cancer or other conditions utilizing the provided phosphonate conjugates.

Abstract: A system for monitoring rotating equipment. The system includes a sensor device that acquires vibration data, acoustic emission data, temperature data, and magnetic flux data of the rotating equipment. The sensor device includes base, holding frame, first integrated circuit, housing, and power source. The first integrated circuit includes a plurality of sensors and a microcontroller configured to receive vibration data, acoustic emission data, temperature data, magnetic flux data from plurality of sensors and determine anomalies of the rotating equipment. The system further comprises an application server that receives vibration data and magnetic flux data, determines revolutions per minute (RPM) data for rotating equipment, and diagnose faults based on processed vibration data and RPM data. The application server further generates a set of features and corresponding feature values and analyzes them to diagnose faults, and predict remaining useful life of the rotating equipment.